[go: up one dir, main page]

FR2825928B1 - Composition pharmaceutique pour le diagnostic, la prevention ou le traitement d'une pathologie tumorale, comprenant un agent modulateur de l'etat polymerisation de l'actine - Google Patents

Composition pharmaceutique pour le diagnostic, la prevention ou le traitement d'une pathologie tumorale, comprenant un agent modulateur de l'etat polymerisation de l'actine

Info

Publication number
FR2825928B1
FR2825928B1 FR0107976A FR0107976A FR2825928B1 FR 2825928 B1 FR2825928 B1 FR 2825928B1 FR 0107976 A FR0107976 A FR 0107976A FR 0107976 A FR0107976 A FR 0107976A FR 2825928 B1 FR2825928 B1 FR 2825928B1
Authority
FR
France
Prior art keywords
actin
diagnosing
polymerization
preventing
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0107976A
Other languages
English (en)
Other versions
FR2825928A1 (fr
Inventor
Christian Auclair
Valerie Amsellem
Martial Hervy
Frederic Subra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
École Normale Supérieure Paris-Saclay
Original Assignee
Ecole Normale Superieure de Cachan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0107976A priority Critical patent/FR2825928B1/fr
Application filed by Ecole Normale Superieure de Cachan filed Critical Ecole Normale Superieure de Cachan
Priority to JP2003506318A priority patent/JP4271026B2/ja
Priority to CA002450845A priority patent/CA2450845A1/fr
Priority to PCT/FR2002/002106 priority patent/WO2002102846A2/fr
Priority to AU2002317259A priority patent/AU2002317259A1/en
Priority to EP02745538A priority patent/EP1432732A2/fr
Publication of FR2825928A1 publication Critical patent/FR2825928A1/fr
Priority to US10/740,266 priority patent/US20040191230A1/en
Application granted granted Critical
Publication of FR2825928B1 publication Critical patent/FR2825928B1/fr
Priority to US12/426,833 priority patent/US20090286720A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FR0107976A 2001-06-18 2001-06-18 Composition pharmaceutique pour le diagnostic, la prevention ou le traitement d'une pathologie tumorale, comprenant un agent modulateur de l'etat polymerisation de l'actine Expired - Fee Related FR2825928B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR0107976A FR2825928B1 (fr) 2001-06-18 2001-06-18 Composition pharmaceutique pour le diagnostic, la prevention ou le traitement d'une pathologie tumorale, comprenant un agent modulateur de l'etat polymerisation de l'actine
CA002450845A CA2450845A1 (fr) 2001-06-18 2002-06-18 Composition pharmaceutique pour le diagnostic, la prevention ou le traitement d'une pathologie tumorale, comprenant un agent modulateur de l'etat de polymerisation de l'actine
PCT/FR2002/002106 WO2002102846A2 (fr) 2001-06-18 2002-06-18 Composition pharmaceutique comprenant un agent modulateur de l'etat de polymerisation de l'actine
AU2002317259A AU2002317259A1 (en) 2001-06-18 2002-06-18 Pharmaceutical composition for diagnosis, prevention or treatment of a tumorous state, comprising a modulator of the actin polymerisation state
JP2003506318A JP4271026B2 (ja) 2001-06-18 2002-06-18 アクチン重合状態の調節剤を含む腫瘍病変の診断、予防又は治療用の薬剤組成物
EP02745538A EP1432732A2 (fr) 2001-06-18 2002-06-18 Composition pharmaceutique comprenant un agent modulateur de l'etat de polymerisation de l'actine
US10/740,266 US20040191230A1 (en) 2001-06-18 2003-12-18 Pharmaceutical composition for the diagnosis, prevention or treatment of a tumoral pathology comprising an agent modulating the polymerization state of actin
US12/426,833 US20090286720A1 (en) 2001-06-18 2009-04-20 Pharmaceutical composition for the diagnosis, prevention or treatment of a tumoral pathology comprising an agent modulating the polymerization state of actin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0107976A FR2825928B1 (fr) 2001-06-18 2001-06-18 Composition pharmaceutique pour le diagnostic, la prevention ou le traitement d'une pathologie tumorale, comprenant un agent modulateur de l'etat polymerisation de l'actine

Publications (2)

Publication Number Publication Date
FR2825928A1 FR2825928A1 (fr) 2002-12-20
FR2825928B1 true FR2825928B1 (fr) 2004-04-02

Family

ID=8864451

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0107976A Expired - Fee Related FR2825928B1 (fr) 2001-06-18 2001-06-18 Composition pharmaceutique pour le diagnostic, la prevention ou le traitement d'une pathologie tumorale, comprenant un agent modulateur de l'etat polymerisation de l'actine

Country Status (7)

Country Link
US (2) US20040191230A1 (fr)
EP (1) EP1432732A2 (fr)
JP (1) JP4271026B2 (fr)
AU (1) AU2002317259A1 (fr)
CA (1) CA2450845A1 (fr)
FR (1) FR2825928B1 (fr)
WO (1) WO2002102846A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0224014D0 (en) * 2002-10-15 2002-11-27 Oxford Glycosciences Uk Ltd A protein involved in therapy
PL1841316T3 (pl) * 2005-01-10 2011-09-30 Univ Rosalind Franklin Medicine & Science Białko CCN3 do zastosowania w leczeniu i diagnozowaniu chorób nerek
US7780949B2 (en) * 2005-01-10 2010-08-24 Rosalind Franklin University Of Medicine And Science Regulation of CCN2 by CCN3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases
CA2691251A1 (fr) * 2007-06-19 2008-12-24 Yoshikazu Ohta Medicament preventif/remede contre le cancer
CN102316902B (zh) * 2009-02-20 2014-09-24 to-BBB控股股份有限公司 基于谷胱甘肽的药物递送系统
US8518395B2 (en) 2010-04-02 2013-08-27 Rosalind Franklin University Of Medicine And Science CCN3 peptides and analogs thereof for therapeutic use
US9114112B2 (en) 2010-04-02 2015-08-25 Rosalind Franklin University Of Medicine And Science CCN3 and CCN3 peptides and analogs thereof for therapeutic uses
US10028906B2 (en) 2016-03-22 2018-07-24 Rosalind Franklin University Of Medicine And Science Method and kit for treating a solid tumor and associated desmoplasia
CN109628452A (zh) * 2019-01-17 2019-04-16 浙江大学 一种抑制肿瘤细胞增殖和迁移的Zyxin基因shRNA及重组载体与应用
CN111620939B (zh) * 2019-10-25 2021-01-01 南京市妇幼保健院 一种用于治疗或辅助治疗卵巢癌的多肽zyx36-58

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586425B2 (en) * 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
ATE324462T1 (de) * 1997-09-04 2006-05-15 Univ Leland Stanford Junior Assays zur detektierung von modulatoren der cytoskeletalen funktion
JP2003518000A (ja) * 1998-12-11 2003-06-03 コールター ファーマシューティカル，インコーポレイティド プロドラッグ化合物およびその調製方法
CA2325806A1 (fr) * 1999-12-03 2001-06-03 Molecular Mining Corporation Methodes de diagnostique et de pronostic de leucemies aigues
FR2806805A1 (fr) * 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS

Also Published As

Publication number Publication date
WO2002102846B1 (fr) 2004-06-03
EP1432732A2 (fr) 2004-06-30
FR2825928A1 (fr) 2002-12-20
US20090286720A1 (en) 2009-11-19
CA2450845A1 (fr) 2002-12-27
AU2002317259A1 (en) 2003-01-02
WO2002102846A2 (fr) 2002-12-27
JP2005504521A (ja) 2005-02-17
JP4271026B2 (ja) 2009-06-03
US20040191230A1 (en) 2004-09-30
WO2002102846A3 (fr) 2004-04-22

Similar Documents

Publication Publication Date Title
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie
FR2825928B1 (fr) Composition pharmaceutique pour le diagnostic, la prevention ou le traitement d'une pathologie tumorale, comprenant un agent modulateur de l'etat polymerisation de l'actine
DK1133989T3 (da) Polymersammensætning til anvendelse i terapi
MA26420A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.
HUP0102612A2 (hu) Fehérje-tirozinfoszfatázokat moduláló vegyületek és ezeket tartalmazó gyógyászati készítmények
EP1638950A4 (fr) Derives de cyclohexylglycine servant d'inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
MA26889A1 (fr) Composition pharmaceutique pour le traitement de la douleur aigue chronique et/ ou neuropathique et des migraines
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
TNSN99055A1 (fr) Derives bicycliques d'acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN04097A1 (fr) Formulations comprenant une cephalosporine et leur utilisation dans le traitement d'infections bacteriennes chez les chats et les chiens.
BR0109650A (pt) 3-cianoquinolinas, 3-ciano-1,6-naftiridinas e 3-ciano-1,7-naftiridinas como inibidores da cinase proteìca
TNSN96104A1 (fr) Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant
DZ2675A1 (fr) Association pharmaceutique pour le traitement d'undysfunctionnement sexuel et compositions la conte nant.
MA26608A1 (fr) Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque.
TNSN99001A1 (fr) Indoles 2,3-substitues servant d'agents anti-inflammatoires et analgesiques
DZ2539A1 (fr) Compositions pharmaceutiques pour le traitement dela résistance à l'insuline.
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
KR960006915A (ko) 췌장염의 치료 조성물
FR2749007B1 (fr) Nouvelle composition de ciment phosphomagnesien comprenant un polymere sous forme de particules
TNSN01076A1 (fr) Associations de secretagogues d'hormone de croissance et d'antidepresseurs, et compositions les contenant
ATE233812T1 (de) Peptide mit pronociceptiveigenschaften
TNSN98123A1 (fr) Formes posologiques de sertraline et procede pour leur preparation
DZ2012A1 (fr) Benzamides pour le traitement de dégénérescences neurologiques.
TNSN99118A1 (fr) Associations therapeutiques pour le traitement de maladies osseuses, et procede pour leur preparation
FR2846559B1 (fr) Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20140228